Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Post by Xbolt3388on Oct 08, 2022 12:55pm
155 Views
Post# 35014109

Biden Health Secretary Has Already Talked To FDA About Marij

Biden Health Secretary Has Already Talked To FDA About Marijhttps://www.marijuanamoment.net/biden-health-secretary-has-already-talked-to-fda-about-marijuana-scheduling-review-which-will-move-quickly/



  •  

“The president was very clear—he wants this done as quickly as possible.”

By Mitch Perry, Florida Phoenix

U.S. Health and Human Services (HHS) Secretary Xavier Becerra said in Tampa Friday that he intends for his agency to move “as quickly as we can” to comply with President Joe Biden’s directive to review the decades-old policy of listing marijuana as a Schedule I drug.

“I think you’re going to find that we’re going to move as quickly as we can but, at the end of the day science is going to take us to a solution,” Becerra told reporters in Tampa after concluding a “Meet and Greet” event with mostly Latino seniors regarding the reduction in prescription drug prices for Medicare patients that were included in the Inflation Reduction Act passed this summer.

That directive to review cannabis’s status was part of Biden’s announcement on marijuana reform released on Thursday, which includes calling on the Department of Justice to develop a process to pardon potentially thousands of people who have federal convictions for marijuana possession.

Becerra said that the review of marijuana’s federal scheduling status will be tasked to the Food and Drug Administration, and that he has already spoken with FDA Commissioner Robert Califf about starting that process.

“The president was very clear—he wants this done as quickly as possible,” Becerra said. “It’s not new science, but there’s lot of information to gather because in many states marijuana has been legalized for either medical purposes or recreational purposes.”



  •  

“The president was very clear—he wants this done as quickly as possible.”

By Mitch Perry, Florida Phoenix

U.S. Health and Human Services (HHS) Secretary Xavier Becerra said in Tampa Friday that he intends for his agency to move “as quickly as we can” to comply with President Joe Biden’s directive to review the decades-old policy of listing marijuana as a Schedule I drug.

“I think you’re going to find that we’re going to move as quickly as we can but, at the end of the day science is going to take us to a solution,” Becerra told reporters in Tampa after concluding a “Meet and Greet” event with mostly Latino seniors regarding the reduction in prescription drug prices for Medicare patients that were included in the Inflation Reduction Act passed this summer.

That directive to review cannabis’s status was part of Biden’s announcement on marijuana reform released on Thursday, which includes calling on the Department of Justice to develop a process to pardon potentially thousands of people who have federal convictions for marijuana possession.

Becerra said that the review of marijuana’s federal scheduling status will be tasked to the Food and Drug Administration, and that he has already spoken with FDA Commissioner Robert Califf about starting that process.

“The president was very clear—he wants this done as quickly as possible,” Becerra said. “It’s not new science, but there’s lot of information to gather because in many states marijuana has been legalized for either medical purposes or recreational purposes.”


<< Previous
Bullboard Posts
Next >>